FAS: Enrolled participants who have received at least one dose of treatment.
The analysis for DOR assessed by investigator was based on the responders in the FAS of each cohort.
","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Duration of Response (DoR), Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.4","upperLimit":"82.3","value":"72.7"},{"groupId":"OG001","lowerLimit":"70.2","upperLimit":"94.3","value":"85"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Disease control rate is defined as the percentage of participants who have a confirmed CR or PR or who have SD per RECIST 1.1, as assessed by ICR","dispersionType":"95% Confidence Interval","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"NUMBER","populationDescription":"RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Disease Control Rate (DCR), Assessed by ICR","type":"SECONDARY","unitOfMeasure":"Percentage"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8"},{"groupId":"OG001","value":"45.0"}]}],"title":"Confirmed Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Confirmed Complete Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"NUMBER","populationDescription":"RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Best Overall Response (BoR) , Assessed by ICR","type":"SECONDARY","unitOfMeasure":"Percentage"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"2.8","value":"1.5"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"2.7","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1","dispersionType":"Inter-Quartile Range","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.
The analysis for TTR assessed by ICR was based on the responders in the RES of each cohort.
","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Time To Response (TTR) , Assessed by ICR","type":"SECONDARY","unitOfMeasure":"Month"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"6.9","value":"5.3"},{"comment":"The upper limit is not calculable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"5.7","upperLimit":"NA","value":"7.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Progression-free survival is defined as time from the date of the first dose of study intervention until progression per RECIST 1.1, as assessed by ICR, or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"FAS: Enrolled participants who have received at least one dose of treatment.\nParticipants who were enrolled but did not subsequently receive study intervention are not included in the analysis.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Progression-Free Survival (PFS) , Assessed by ICR","type":"SECONDARY","unitOfMeasure":"Month"},{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit is not calculable.","groupId":"OG000","lowerLimit":"10.7","upperLimit":"NA","value":"13.5"},{"comment":"The NAs are not calculable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Overall survival is defined as the time from the date of the first dose of study intervention to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"FAS: Enrolled participants who have received at least one dose of treatment.\nParticipants who were enrolled but did not subsequently receive study intervention are not included in the analysis.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Month"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.0","upperLimit":"5.6","value":"4.3"},{"groupId":"OG001","lowerLimit":"5.5","upperLimit":"8.5","value":"7.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Progression-free survival is defined as time from the date of the first dose of study intervention until progression per RECIST 1.1, as assessed by investigator, or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"FAS: Enrolled participants who have received at least one dose of treatment.\nParticipants who were enrolled but did not subsequently receive study intervention are not included in the analysis.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Progression-Free Survival (PFS) , Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"Month"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.6","upperLimit":"85.5","value":"76.6"},{"groupId":"OG001","lowerLimit":"70.2","upperLimit":"94.3","value":"85.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by investigator, or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"NUMBER","populationDescription":"RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Disease Control Rate (DCR), Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"Percentage"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Confirmed complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2"},{"groupId":"OG001","value":"37.5"}]}],"title":"Confirmed partial response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"NUMBER","populationDescription":"RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Best Overall Response (BoR) , Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"Percentage"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"1.6","value":"1.4"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"1.4","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"FAS: Enrolled participants who have received at least one dose of treatment.\nParticipants who were enrolled but did not subsequently receive study intervention are not included in the analysis.
The analysis for TTR assessed by investigator was based on the responders in the FAS of each cohort.
","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Time To Response (TTR) , Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"Month"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.45","value":"713.9"},{"groupId":"OG001","spread":"24.47","value":"569.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"PK parameters of Total Anti-TROP2 Antibody_Area under the curve","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set:Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.
The analysis for AUC was based on the patients with intensive PK collection of each cohort.
","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ Total Anti-TROP2 Antibody","type":"SECONDARY","unitOfMeasure":"day*ug/mL"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.09","value":"137.8"},{"groupId":"OG001","spread":"22.38","value":"121.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"PK parameters of Total Anti-TROP2 Antibody_Maximum observed concentration","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set:Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Total Anti-TROP2 Antibody","type":"SECONDARY","unitOfMeasure":"ug/mL"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.11","value":"668.3"},{"groupId":"OG001","spread":"22.38","value":"504.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"PK parameters of Dato-DXd_Area under the curve","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set:Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.
The analysis for AUC was based on the patients with intensive PK collection of each cohort.
","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _Dato-DXd","type":"SECONDARY","unitOfMeasure":"day*ug/mL"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.18","value":"136.4"},{"groupId":"OG001","spread":"18.12","value":"115.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"PK parameters of Dato-DXd_Maximum observed concentration","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set:Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Dato-DXd","type":"SECONDARY","unitOfMeasure":"ug/mL"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.64","value":"17.60"},{"groupId":"OG001","spread":"33.09","value":"17.66"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"PK parameters of MAAA-1181a_Area under the curve","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set:Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.
The analysis for AUC was based on the patients with intensive PK collection of each cohort.
","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ MAAA-1181a","type":"SECONDARY","unitOfMeasure":"day*ng/mL"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.09","value":"2.484"},{"groupId":"OG001","spread":"42.31","value":"2.463"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"PK parameters of MAAA-1181a_Maximum observed concentration","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set:Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ MAAA-1181a","type":"SECONDARY","unitOfMeasure":"ng/mL"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.40","upperLimit":"7.17","value":"2.00"},{"groupId":"OG001","lowerLimit":"0.90","upperLimit":"6.83","value":"1.70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"PK parameters of Total Anti-TROP2 Antibody_Time to maximum plasma concentration","dispersionType":"Full Range","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"PK analysis set: Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Total Anti-TROP2 Antibody","type":"SECONDARY","unitOfMeasure":"Hour"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.12","upperLimit":"7.17","value":"1.92"},{"groupId":"OG001","lowerLimit":"0.90","upperLimit":"5.22","value":"1.77"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Time to maximum plasma concentration","dispersionType":"Full Range","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"PK analysis set: Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Dato-DXd","type":"SECONDARY","unitOfMeasure":"h"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.67","upperLimit":"24.22","value":"5.00"},{"groupId":"OG001","lowerLimit":"4.77","upperLimit":"25.07","value":"4.98"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"PK parameters of MAAA-1181a_Time to maximum plasma concentration","dispersionType":"Full Range","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"PK analysis set: Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _ MAAA-1181a","type":"SECONDARY","unitOfMeasure":"Hour"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"36.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"The prevalence of ADA (positive at any visit)","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"NUMBER","populationDescription":"ADA Evaluable Set: Participants in the FAS with a non-missing baseline Dato-DXd ADA result and at least one post-baseline Dato-DXd ADA result.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Immunogenicity of Dato-DXd","type":"SECONDARY","unitOfMeasure":"percentage"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.53","upperLimit":"12.6","value":"6.7"},{"comment":"The upper limit is not calculable due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"5.9","upperLimit":"NA","value":"8.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by ICR, or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.
The analysis for DOR assessed by ICR was based on the responders in the RES of each cohort.
","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 12 months post last subject dose with an average of 12 months follow up. NSCLC cohort: from enrollment to 6 months post last subject dose with an average of 8 months follow up.","title":"Duration of Response (DoR), Assessed by ICR","type":"SECONDARY","unitOfMeasure":"Month"}]},"participantFlowModule":{"groups":[{"description":"Final Analysis with DCO on 06May2024","id":"FG000","title":"TNBC Cohort"},{"description":"Primary Analysis with DCO on 09Oct2023","id":"FG001","title":"NSCLC Cohort"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"9"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"31"}],"type":"Ongoing participants at NSCLC primary analysis DCO"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"40"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"29"},{"comment":"NSCLC cohort has not reached final analysis.","groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"40"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Overall 168 participants were screened at 23 centers in China.\nA total of 119 participants were treated with Dato-DXd.
Note: 3 centers screened both TNBC participants and NSCLC participants.
","recruitmentDetails":"This Phase 1/2, open-label, multiple-cohort, single-arm study was conducted in participants with Advanced Non-Small-Cell Lung Cancer (NSCLC) and Triple-Negative Breast Cancer(TNBC) in China.